Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 46480.00

カスタマーフィードバック(8)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    a Immunofluorescence of HA–cGAS in transfected HCA2-TERT cells exposed to etoposide (100 μg/ml) for 4 h. b, Immunoblot of endogenous cGAS in the cytoplasmic and nuclear fractions of HCA2-TERT cells treated with etoposide for the indicated times

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

  • j, Immunoblot of cell lysates of PC-9 cells that stably express HA–cGAS, transfected with either shCtrl or shBLK after etoposide (100 μg ml−1) treatment for 4 h.

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M{TseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP M4K2[VI2QTZyMkiy
KellyCis83 NW\t[GpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnUcI0xUUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> M{\a[lI2QTZyMkiy
SK-N-AS MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NWjCS2JiOjV7NkCyPFI>
SK-N-ASCis24 NXjsSXNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBSWlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= M2rOVVI2QTZyMkiy
U87 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXQNE02OCEQvF2= Mof4OFghcA>? MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? NFvoeoMzPTd3MEK3Ny=>
HCT116 M1;vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLmc3E1OC53LUKuOUDPxE1? MoLpOFjDqGkEoB?= MorsTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NV7vWVBFOjV5NE[3OlM>
HT-29 M{P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMlUuOi53IN88US=> MnLhOFjDqGkEoB?= MVPJR|UxRTdwMtMgxtHDqDFwMEVCpO69VQ>? M3q5eVI2PzR4N{[z
Caco2 NWPxPXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fMeFAvPS1{LkWg{txO MVW0POKhcMLi NHXwUnhKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= MlzJNlU4PDZ5NkO=
COLO 205 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjwNE42NTJwNTFOwG0> M2jaRlQ5yqCqwrC= NWHteW9CUUN3ME2xMlYyyqEEsdMgNE4xOsLizszN NX2wTpg{OjV5NE[3OlM>
SW480 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWwMlUuOi53IN88US=> MmXVOFjDqGkEoB?= MkPiTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP NFLNTnMzPTd2Nke2Ny=>
HEK293T M4njc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fDXVEuPSEQvF2= MmX0OFjDqGkEoB?= NUXk[JVwUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN M3LWflI2PzR4N{[z
Hep3B  M3X4R2Z2dmO2aX;uJGF{e2G7 NE\qOmgyOCEQvF2= NFL4WI81QMLiaNMg MlKydoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> MV2yOVY{OzV4NB?=
Hep3B  MlLQSpVv[3Srb36gRZN{[Xl? MnnvNE4yNTFyIN88US=> NHLnZ4QzPCCq MY\zeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? M4Tkc|I2PjN|NU[0
HEK293 MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrKVVNKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= MYiyOVYxOzF{Mh?=
DU145 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDzXIhKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= NWXjco5UOjV4MEOxNlI>
HCT15 M4D4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHhTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP MlPUNlU3ODNzMkK=
T47D NF;rWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvoNW5KSzVyPUOuNVjDqMLzwrCwMlEyyqEQvF2= Mof1NlU3ODNzMkK=
SMMC-7721 NGHM[|JHfW6ldHnvckBCe3OjeR?= NHniflA1OCEQvF2= NVr0NJNjPDhiaB?= NUW5O2pbTE2VTx?= M4j1W4lv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v NGfnSmMzPTV2NEO2NS=>
MDA-MB-231 NEjJWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PS[FczyqCq NVf4[3U1UUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= MnrZNlU1QDZ{MUm=
MCF-7 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qSYc4OsLiaB?= MV;JR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? NY\udXc1OjV2OE[yNVk>
Jurkat NYi5[YxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;5bnF2PzMEoHi= NEK0[|VKSzVyPUGuNuKhyrIEoEGuOeKh|ryP NV6yTWdMOjV2OE[yNVk>
HeLa NFuxZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NuKhcA>? NIjOcmVKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP NHfwTY0zPTR6NkKxPS=>
MCF7  MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m0ZlUuOTByIN88US=> NVnYSXB1PyCm NVrGb4ZncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFvv[XIzPTR5Mk[xPS=>
K562 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3NuKhcA>? NGjVNXBKSzVyPUCuNlnDqM7:TR?= NFj1XG4zPTJ6Mk[1Ny=>
K/VP.5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG3NuKhcA>? NWH1TXVTUUN3ME20MlnDqM7:TR?= M3Xqe|I2Ojh{NkWz
SH-EP  NGfDZlJHfW6ldHnvckBCe3OjeR?= M1GwZlIxyqEQvHevcYw> NF35XHczPMLiaB?= MX3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS MmL0NlUzPjF7OEG=
SCC25 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSyOOKhcA>? NXmyZYFDUUN3ME20N{4{yqEEsdMgNU4yOsLizszN MX2yOVIzODd{OR?=
CAL27 NWrRcIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC4NlTDqGh? NEP2VG9KSzVyPUWyMlHDqMLzwrCxMlA6yqEQvF2= MojFNlUzOjB5Mkm=
FaDu NEfKN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjqNlTDqGh? MWDJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP MV2yOVIzODd{OR?=
SCC25 NXvOe|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvhcpc1QMLiaB?= MXfJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP NYrxeGY1OjV{MkC3Nlk>
CAL27 NXO4O2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TSU|Q5yqCq NFS4XpVKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN MY[yOVIzODd{OR?=
FaDu MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37UUFQ5yqCq MWDJR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? NIfpV3czPTJ{MEeyPS=>
SCC25 NH62SJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HUNVczyqCq NGC3eFRKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= MXWyOVIzODd{OR?=
CAL27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfaO|LDqGh? NF\rWZFKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= MWOyOVIzODd{OR?=
FaDu NGjEZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDsO|LDqGh? MoT6TWM2OD13LkCyxsDDucLiMT6xOeKh|ryP M1H2fFI2OjJyN{K5
MCF-7 NF[5UYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fKclQ5yqCqwrC= NE\GOHFFVVOR NVXZdWs5UUN3ME23MlLDqMLzwrCwMljDqM7:TR?= NXvRZmVGOjV{MU[zO|g>
T-47D MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfwT481QMLiaNMg M2TwWGROW09? NXnTZol5UUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= M1iyOFI2OjF4M{e4
MDA-MB-231 NVPXfWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe0POKhcMLi MkO4SG1UVw>? NYTWZ5ZzUUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= M3KwSVI2OjF4M{e4
DU145 Mm\BRZBweHSxc3nzJGF{e2G7 M{S2PFExNTFyMDFOwG0> NUTTW5d[QCCq M1O5VmROW09? Ml\DbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MXeyOVE1QTZ6MR?=
DU145 stem-like NXTXNZhbSXCxcITvd4l{KEG|c3H5 NH;6[WMyOC1zMECg{txO NHW3NWc5KGh? NXnwRYxyTE2VTx?= M3LJWolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYOyOVE1QTZ6MR?=
DU145 MVfGeY5kfGmxbjDBd5NigQ>? M3;QUlExNTFyMDFOwG0> M3rud|IhcA>? NF[3[|NFVVOR NEXCdXJqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mkf2NlUyPDl4OEG=
DU145 stem-like M3ezSmZ2dmO2aX;uJGF{e2G7 NWe2eoVNOTBvMUCwJO69VQ>? MVSyJIg> NHTuUIRFVVOR NUDoXlI5cW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHflOI0zPTF2OU[4NS=>
UW228-3 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[wMlAyNTNyMDFOwG0> NUXE[ndZPDhiaB?= MmTsSG1UVw>? NYjzWGVSUUN3ME2wMlk6yqEQvF2= M4K3N|I2OTF7MUi1
NSCs MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3xfIRtOC5yMT2zNFAh|ryP MXy0PEBp NY\1XHBbTE2VTx?= NHXYNJhKSzVyPUCuN{0{yqEQvF2= MVmyOVEyQTF6NR?=
MKL-1  MWjGeY5kfGmxbjDBd5NigQ>? MY[xNE0yODByIH7N M1;4XFQh\A>? NUm0cZNycW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MkLDNlUyOTZ5NUS=
MCF7 EV NFLCe|dHfW6ldHnvckBCe3OjeR?= M3z5flExNTFyMDFOwG0> MX6y5qCKcA>? NFPvSnlqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? M2DuelI2ODh6MkCz
MCF 7BMI1 MXfGeY5kfGmxbjDBd5NigQ>? NEjFUIwyOC1zMECg{txO M{OxbFLjiImq MnzRbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NYPJbW5bOjVyOEiyNFM>
MCF7 EV Mk\LSpVv[3Srb36gRZN{[Xl? NIfMd3kyOC1zMECg{txO NGHadHcz6oDLaB?= MXfFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= NXfRSmo5OjVyOEiyNFM>
MCF7 BMI1 M3e2OmZ2dmO2aX;uJGF{e2G7 M4Dzc|ExNTFyMDFOwG0> MXWy5qCKcA>? NUi5XVF4TVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v M3n6XFI2ODh6MkCz
HepG2 NWi2cWVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\XPFFDTE2VT9Mg NUfJc2F3UUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> NFLyW5YzPTB5OEOxNS=>
MOLT-3 M3PiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\EUXNQyqB? M2nkTGlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN M1\BV|I2ODd6M{Gx
HT1080 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXaNU0yODBizszN NWHCdIhrPC9{ND:0PEBp MoT1SG1UV8Li Ml\wbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MnLINlUxPzhyNkS=
HT1080 NWHNN2ozTnWwY4Tpc44hSXO|YYm= Mk\zNE4xODBzLUGwNEDPxE1? MWKxMVI1KGh? M2fTbWROW00EoB?= MXPpcoR2[2W|IICtdFU{MHOnckG1LUBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NV3scHV6OjVyN{iwOlQ>
HT1080 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHISGpOOC5yMECxMVExOCEQvF2= M2XkU|I1KGh? MnTKSG1UV8Li NHnobVFk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz M2PLVlI2ODd6ME[0
HD-MY-Z MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D2NlI1NzR6L{eyJIg> NWrjTlFjUUN3MP-8olExOCEQvF2= MWqyOVA1QDJ|Nh?=
DOHH-2 M{T5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqyNlQhcA>? NFTK[WdKSzVy78{eNVAxKM7:TR?= NXvMeXE4OjVyNEiyN|Y>
DOHH-2 NHixdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH3SnI1QCCq MnPDTWM2OD1zOT65xsDPxE1? NILISZIzPTB2OEKzOi=>
DOHH-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW3NkBp Mn7VTWM2OD13wrFOwG0> MonsNlUxPDh{M{[=
REH M{DWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf2RpN6OjRiaB?= M4T0UmlEPTB;MD6wNlfDqM7:TR?= MnLhNlUxPDh{M{[=
REH M2HoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHMOFghcA>? MX3JR|UxRTBwMEG0xsDPxE1? NFTiRYwzPTB2OEKzOi=>
REH NID5cmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPlSnJMPzJiaB?= MVzJR|UxRTBwMEG1xsDPxE1? NVv2To1OOjVyNEiyN|Y>
HH NYrsTnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXuRlBSOjRiaB?= NHr1RY9KSzVyPUGwOE44yqEQvF2= MXqyOVA1QDJ|Nh?=
HH Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XzT|Q5KGh? MoeyTWM2OD12OD62xsDPxE1? MYeyOVA1QDJ|Nh?=
HH MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljlO|IhcA>? MnTBTWM2OD1zND63xsDPxE1? NHTndGQzPTB2OEKzOi=>
HuT-78 Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DyTFI1KGh? NYTCfJNDUUN3ME25MlPDqM7:TR?= M2fqU|I2ODR6MkO2
HuT-78 NIjQVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW0PEBp M3Tx[mlEPTB;ND6zxsDPxE1? NYm4RWxEOjVyNEiyN|Y>
HuT-78 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK3NkBp MWHJR|UxRTRwMtMg{txO NWr6PZRqOjVyNEiyN|Y>
OPM-2 NVviVlRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyyOEBp M{HPVGlEPTB;MkSuNeKh|ryP Mnv0NlUxPDh{M{[=
OPM-2 M2rLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PBN|Q5KGh? M1nG[WlEPTB;NNMg{txO NYrGbmNyOjVyNEiyN|Y>
OPM-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;PUWg4OiCq M2fwNmlEPTB;MT6zxsDPxE1? NF\vWIUzPTB2OEKzOi=>
RPMI-8226 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfUNlQhcA>? MUPJR|UxRTFyNj62xsDPxE1? MlLDNlUxPDh{M{[=
RPMI-8226 M{ewW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HDb|Q5KGh? NVPZXI5wUUN3ME25NU4yyqEQvF2= Mk\BNlUxPDh{M{[=
RPMI-8226 M1nRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO3NkBp MVLJR|UxRTF2LkpCpO69VQ>? M3zTRlI2ODR6MkO2
U-266 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2yOEBp NULZTZhSUUN3ME24Ok4zyqEQvF2= M{HlNVI2ODR6MkO2
U-266 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;BS2I1QCCq MYDJR|UxRTZ6LkVCpO69VQ>? M1jIR|I2ODR6MkO2
U-266 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp Mn\VTWM2OD1{Nz60xsDPxE1? MWWyOVA1QDJ|Nh?=
Kelly NFXvVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP6c3IxNTFyIN88US=> MoroO|LDqGh? MlrKTWM2OD1zLkWxPOKh|ryP MUKyOVAxQDlyMB?=
SH-SY5Y  MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TYUlAuOTBizszN MWW3NuKhcA>? NXvUfZNPUUN3ME2wMlc2PMLizszNxsA> M4D4SlI2ODB6OUCw
SK-N-AS NVfGbpplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUflNXdCOC1zMDFOwG0> Mn\SO|LDqGh? MVLJR|UxRTFwN{GyxsDPxE4EoB?= MmjnNlUxODh7MEC=
SK-N-DZ NIX3XYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorONE0yOCEQvF2= MnvoO|LDqGh? M1vzXmlEPTB;NT60PFXDqM7:TR?= NEfiU2gzPTByOEmwNC=>
HepG2 NVO0VJNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe0POKhcA>? NFXJUYFFVVORwrC= NH:wZ3RKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN M3nBelI1QTl4MUO2
A549 NGHE[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDK[Vk1QMLiaB?= MlLhSG1UV8Li MUjJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NUPXeZVQOjR7OU[xN|Y>
MCF7 NEnIWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor4OFjDqGh? M1zBcWROW00EoB?= MWTJR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= NVjDepBUOjR7OU[xN|Y>
HL-60  NWnBXGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnZUmFPPzMEoHi= MYjJR|UxRTBwMUNihKXPxE1? M3LVcVI1QTl|MEG0
HL-60[R] MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW3NuKhcA>? M4fQd2lEPTB;Mz6xNwKBjc7:TR?= M4m5WFI1QTl|MEG0
MIAPACA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrrS2k2OD1zLkOgxtEhOC5yMzFOwG0> M{mwUVI1QTV|OEKx
MCF-7 M1L1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G3WWdKPTB;MD6yOUDDuSByLkGg{txO M1XtSVI1QTV|OEKx
HeLa MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDHTVUxRTBwNkSgxtEhOC52IN88US=> MYSyOFk2Ozh{MR?=
MO59K  M{HCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfzdGVlPyCm NXHtWmdGUUN3ME2wMlE46oDHzszN NYDLUmlUOjR7NUO1OlE>
MO59J NX7ZbpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW3JIQ> NGKzOWpKSzVyPUCuNgKBjc7:TR?= NY\JUVFPOjR7NUO1OlE>
ME 180 M4rjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW3cVQ1QMLiaNMg MV7JR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? NVPQV2d7OjR7NUOwNlc>
MCF-7 NFHieGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HLOlQ5yqCqwrC= NGHLdodKSzVyPUKzMlkhyrFiMD6z5qCG|ryP MYSyOFk2OzB{Nx?=
HeLa MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzDOFjDqGkEoB?= MmHaTWM2OD12LkexJOKyKDFwNPMAie69VQ>? NXGxSmh{OjR7NUOwNlc>
MDA-MB-453 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\UeFQ5yqCqwrC= M2XxNGlEPTB;MUKuOUDDuSByLki15qCG|ryP NHmwXVQzPDl3M{CyOy=>
MDA-MB-231 NEX0[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPDdZE1QMLiaNMg NH7KZWJKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= MnTvNlQ6PTNyMke=
PC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjiXIoyPDkEoHlCpC=> MWLJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? MXOyOFk2OzB{Nx?=
HT-29 NUi2TVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfmVXY2PDkEoHlCpC=> MVvJR|UxRTJzLkS1JOKyKDNwOEhihKXPxE1? MmLFNlQ6PTNyMke=
BGC-823 NX3YT5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG0POKhcMLi MlzxTWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP NIrnbmUzPDd7M{i3Oy=>
HeLa NGD4VFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf5cII4PDkEoHlCpC=> NF\XSnhKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NVTMN4Q6OjR5OUO4O|c>
A549 NX;UfWJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUO0POKhcMLi M{\kOWlEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= NHnSSYkzPDd7M{i3Oy=>
HK-2 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPzcI81QMLiaNMg NHvMWHFKSzVyPUmuNVchyrFiMT61PQKBjc7:TR?= NWPpW5pKOjR5OUO4O|c>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+H2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
in solvent
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Recruiting Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03669783 Not yet recruiting Childhood Renal Tumor Assistance Publique Hopitaux De Marseille January 1 2019 Phase 3
NCT03742115 Not yet recruiting Hemophagocytic Lymphohistiocytosis Beijing Friendship Hospital December 1 2018 Phase 3
NCT03711305 Not yet recruiting Extensive-stage Small Cell Lung Cancer Jiangsu HengRui Medicine Co. Ltd. December 2018 Phase 3
NCT03579927 Not yet recruiting CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 2018 Phase 1|Phase 2
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID